Effects of the angiotensin-converting enzyme inhibitor alacepril in dogs with mitral valve disease

The Journal of Veterinary Medical Science

Yohei YAMASHITA¹  Makoto HITOMI²  Noriko ISAYAMA³  Satoshi HOSAKA⁴  Yasutomo HORI⁵  Takahiro MIMURA⁶  Kensuke NAKAMURA⁷  Nobuyuki KANNO⁸ 

[1]Ebisu Animal Hospital, 3-3-43 Nishitaga, Taihaku, Sendai, Miyagi 982-0034, Japan

[2]Hitomi Animal Hospital, 37-7 Yoshidakamiadachicho, Sakyo, Kyoto 606-8307, Japan

[3]Hosaka Animal Hospital, 4-17-1 Nihonmatsu Midori, Sagamihara, Kanagawa 252-0137, Japan

[4]Laboratory of Small Animal Internal Medicine II, School of Veterinary Medicine, Kitasato University, 23-35-1 Higashi, Towada, Aomori 034-8628, Japan

[5]School of Veterinary Medicine, Rakuno Gakuen University, 582 Midori-machi, Bunkyodai, Ebetsu, Hokkaido 069-8501, Japan

[6]Uenonomori Animal Clinic, 1-5-11 Yanaka Taito, Tokyo 110-0001, Japan

[7]University of Miyazaki, 1-1 Gakuenkibanadai-nishi, Miyazaki 889-2192 Japan

[8]Veterinary Internal Medicine, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa, Kanagawa 252-8510, Japan

关键词: alacepril;    canine;    cough;    heart failure;    vasodilator;   

DOI  :  10.1292/jvms.17-0557

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

Alacepril is a relatively novel angiotensin-converting enzyme inhibitor; however, the safety, tolerance, and efficacy of alacepril in terms of cough suppression in dogs with mitral valve disease (MVD) remain unknown. The aim of this study was to investigate the safety, tolerance, and cough suppression efficacy of alacepril in dogs with MVD. This was a multi-center, prospective study. Forty-two dogs with echocardiographic or radiographic evidence of cardiac enlargement in addition to cough were enrolled. Dogs were treated with alacepril (1.0–3.0 mg/kg/day) for at least 4 weeks. One dog (2.4%) developed complications, including appetite loss, lethargy, and vomiting. Thirty-six dogs were re-evaluated after 4 weeks of treatment. Cough resolved or improved in 20 dogs (55.6%) after treatment. Based on the efficacy of alacepril, the dogs were divided into an effective group (n=20) and an ineffective group (n=16). After treatment, the left ventricular end-diastolic internal diameter corrected for body weight was significantly increased from baseline in the ineffective group but was significantly decreased in the effective group. Univariate binomial logistic regression analyses showed that high atrial natriuretic peptide level, N-terminal pro-B-type natriuretic peptide level, and E wave velocity at baseline were significantly correlated with alacepril inefficacy. Alacepril as treatment for MVD is well tolerated in most dogs, and different conditions of cardiac loading may influence the effect of the drug. Alacepril is expected to improve the quality of life of dogs with early stage MVD.

【 授权许可】

Unknown